Compare AVPT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVPT | ANIP |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | United States | United States |
| Employees | 3443 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 1999 |
| Metric | AVPT | ANIP |
|---|---|---|
| Price | $10.01 | $78.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $16.64 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.3M | 294.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $25.00 | $21.01 |
| Revenue Next Year | $19.63 | $17.59 |
| P/E Ratio | $1,348.94 | ★ $23.94 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $8.84 | $56.71 |
| 52 Week High | $20.25 | $99.50 |
| Indicator | AVPT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 53.02 |
| Support Level | $9.86 | $78.80 |
| Resistance Level | $10.40 | $83.58 |
| Average True Range (ATR) | 0.37 | 2.41 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 75.56 | 46.30 |
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.